Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study on the Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock (SEISMiC)

NCT04325035 is registered in ClinicalTrials.gov with Windtree Therapeutics as lead sponsor.

NCT NCT04325035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04325035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study on the Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock (SEISMiC)
Lead sponsor
Windtree Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
September 28, 2020
Completion date
October 30, 2024
Enrollment
90 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

cardiogenic shock